Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Molecular Testing in Early and Advanced NSCLC

December 20th 2021

Solange Peters, MD, PhD, and Tony SK Mok, MD, delve into the importance of molecular testing for EGFR mutant non-small cell lung cancer, including guidelines and commonly found barriers.

IMpower133 Trial for Extensive-Stage SCLC

December 17th 2021

Stephen Liu, MD, reviews outcomes from the IMpower133 trial and comments on the current standard of care for the first-line treatment of extensive-stage SCLC.

Treatment Options for Limited-Stage SCLC

December 17th 2021

John V. Heymach, MD, PhD, provides an overview of small cell lung cancer (SCLC), and Ani Balmanoukian, MD, reviews available treatment options for limited-stage disease.

Dr. Bestvina on the Emerging Role of Neoadjuvant Chemoimmunotherapy in Lung Cancer

December 16th 2021

Christine Bestvina, MD, discusses the emerging role of neoadjuvant chemoimmunotherapy in lung cancer.

TROPION-LUNG01 Trial to Unveil Novel ADC Potential in Heavily Pretreated NSCLC

December 16th 2021

Preliminary research with datopotamab deruxtecan has shown a promising, unprecedented duration of response in heavily pretreated patients with non–small cell lung cancer.

Dr. Aggarwal the Significance of the IMpower010 Trial in PD-L1+ NSCLC

December 15th 2021

Charu Aggarwal, MD, MPH, discusses the significance of the phase 3 IMpower010 trial in patients with PD-L1–positive non–small cell lung cancer.

Treatment of Advanced NSCLC Following Progression on Immunotherapy

December 10th 2021

Lung cancer experts provide insight on updates from key clinical trials presented at ESMO 2021 on PD-1 inhibitor–resistant NSCLC.

Role of Immunotherapy in Early Stage NSCLC Treatment

December 10th 2021

Dr Heather Wakelee reviews results from the IMpower110 study for first-line metastatic NSCLC treatment.

Dr. Arnaoutakis on the ADAURA Trial Examining Osimertinib in EGFR-Mutant Lung Cancer

December 8th 2021

Konstantinos Arnaoutakis, MD, discusses the phase 3 ADAURA trial examining osimertinib in the adjuvant treatment of patients with EGFR-mutant lung cancer.

Community Perspectives in Non–Small Cell Lung Cancer

December 8th 2021

In this clinical case review, a panel of community experts discusses the management of immunotherapy in patients with NSCLC, reflects on factors affecting treatment selection and sequencing, and examines the evolving landscape of immunotherapy-based treatment approaches.

Dr. Bestvina on Challenges With Interpreting Molecular Reports in Lung Cancer

December 6th 2021

Christine Bestvina, MD, discusses challenges with interpreting molecular reports in lung cancer.

FDA Approval Sought for Poziotinib in HER2 Exon 20–Mutated NSCLC

December 6th 2021

A new drug application seeking the approval of poziotinib as a potential therapeutic option for patients with previously treated locally advanced or metastatic non–small cell lung cancer with HER2 exon 20 insertion mutations has been submitted to the FDA.

Updates From CheckMate 9LA and POSEIDON Studies in Advanced NSCLC

December 3rd 2021

Heather Wakelee, MD, shares updates from the CheckMate 9LA study, and Vamsidhar Velcheti, MD, reviews key data from the phase 3 POSEIDON study for patients with NSCLC.

Chemoimmunotherapy in Advanced NSCLC Treatment

December 3rd 2021

Experts in lung cancer discuss recent updates from ESMO 2021 and IASLC 2021 WCLC on combination immunotherapy plus chemotherapy for the treatment of advanced NSCLC.

Dr. Leal on the Evolution of Treatment in EGFR Exon 20 Insertion+ NSCLC

December 2nd 2021

Ticiana Leal, MD, discusses the evolution of treatment in EGFR exon 20 insertion–positive non–small cell lung cancer.

Atezolizumab Provides Option for Patients With NSCLC at High Risk of Recurrence

December 2nd 2021

Nasser Khaled Altorki, MD, provides insight on the results of the IMpower010 trial as well as post hoc analyses from the trial and what they signal for the remainder of this patient population.

Dr. Garon on the Potential Clinical Implications of the TROPION-Lung01 Trial in NSCLC

December 1st 2021

Edward B. Garon, MD, discusses the potential impact of the ongoing, phase 3 TROPION-LUNG01 trial in non–small cell lung cancer.

FDA Issues Complete Response Letter to Plinabulin for Chemo-Induced Neutropenia

December 1st 2021

The FDA has issued a complete response letter to the new drug application seeking the approval of plinabulin in combination with granulocyte colony-stimulating factor for the prevention of chemotherapy-induced neutropenia.

Academic Perspectives in Non-Small Cell Lung Cancer

December 1st 2021

In this clinical case review, academic experts share insights into the disease management of patients with NSCLC, discuss factors impacting treatment selection and sequencing strategies, and evaluate the evolving landscape of immunotherapy-based regimens.

Dr. Bordoni on the Utility of Adjuvant Atezolizumab in the Adjuvant Setting in NSCLC

November 30th 2021

Rodolfo Bordoni, MD, discusses the utility of atezolizumab in the adjuvant setting in non–small cell lung cancer.